Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Benchmark Holdings plc: TR-1: Standard form for notification of major holdings | 1 | Oslo Børs | ||
BENCHMARK HOLDINGS Aktie jetzt für 0€ handeln | |||||
Mo | Benchmark Holdings plc: Rule 2.9 Announcement and Total Voting Rights | 2 | Oslo Børs | ||
Mo | Benchmark Hlgs PLC - Rule 2.9 Announcement and Total Voting Rights | - | RNS | ||
Mo | Benchmark Holdings plc: PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code | - | Oslo Børs | ||
28.05. | Benchmark Holdings plc: Notice of Interim Results | 3 | Oslo Børs | ||
27.05. | Benchmark Hlgs PLC - Notice of Interim Results | - | RNS | ||
26.05. | Benchmark Holdings plc: Financial calendar | 1 | Oslo Børs | ||
23.05. | Benchmark Holdings planning to go private after sale of Benchmark Genetics | 1 | SeafoodSource | ||
23.05. | Benchmark Holdings kündigt Kapitalrückzahlung und Pläne zur Privatisierung an | 6 | Investing.com Deutsch | ||
23.05. | Benchmark Holdings announces capital return and plans to go private | 2 | Investing.com | ||
23.05. | Benchmark Holdings plc: Update on Return of Capital Intention to Cancel Admission to Trading on AIM and Euronext Growth Oslo Appointment of Nominated Adviser and Broker Directorate Changes and AIM Rule 17 Updates Proposed Re-Registration Notice of General | 1 | Oslo Børs | ||
23.05. | Benchmark Hlgs PLC - Update on Return of Capital and Proposed Delisting | 1 | RNS | ||
30.04. | Benchmark Holdings plc: Total Voting Rights | - | Oslo Børs | ||
30.04. | Benchmark Hlgs PLC - Total Voting Rights | - | RNS | ||
16.04. | Benchmark Holdings plc: Update on Strategy for the Continuing Business and Return of Capital | 1 | Oslo Børs | ||
16.04. | Benchmark Hlgs PLC - Update on Strategy and Return of Capital | - | RNS | ||
15.04. | Benchmark Holdings plc: Completion of Bond Redemption | 2 | Oslo Børs | ||
15.04. | Benchmark Hlgs PLC - Completion of Bond Redemption | - | RNS | ||
01.04. | Notice of exercise of call option relating to Benchmark Holdings plc's senior unsecured bonds | 3 | Oslo Børs | ||
01.04. | Benchmark Hlgs PLC - Notice of exercise of call option, bond redemption | - | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,430 | +4,38 % | Knapp vorbei am Aktien-Desaster: Stehen bei Bayer jetzt alle Zeichen auf Rallye? | Noch in der letzten Woche sah es für die Bayer-Aktie an der Börse gar nicht gut aus. Doch schon am Montag haben sich die Vorzeichen geändert. Was erwartet Anleger jetzt? Damit war nicht zu rechen. Noch... ► Artikel lesen | |
NOVO NORDISK | 63,96 | +0,13 % | Klare Kante aus Europa: Novo Nordisk und Co setzen ein Zeichen | Europa wird oft als schwerfällig, bürokratisch und wirtschaftlich träge abgestempelt. Doch ein genauer Blick auf die Börsenlandschaft zeigt: Inmitten globaler Unsicherheit befindet sich ein neues Kraftzentrum.... ► Artikel lesen | |
GSK | 18,055 | +1,21 % | BERENBERG stuft GSK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat GSK nach gutem Lauf bei unverändertem Kursziel von 1600 Pence von "Buy" auf "Hold" abgestuft. Die Kursentwicklung des Pharmakonzerns sei in... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
INNOCAN PHARMA | 0,106 | +1,44 % | Breaking News: Innocan Q1-25 Zahlen! Mit Wachstum ins neue Jahr! | ||
EYEPOINT PHARMACEUTICALS | 7,164 | -0,25 % | EyePoint advances with Duravyu Phase III trial | ||
EDWARDS LIFESCIENCES | 68,09 | +0,55 % | Edwards Lifesciences Corporation: Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes | Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
MYDECINE INNOVATIONS GROUP | 0,010 | +400,00 % | Mydecine Innovations Group Inc (2): Mydecine has no material changes | ||
HAPPY BELLY FOOD GROUP | 0,705 | +3,68 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Signs A 10 Unit Development Agreement for the Greater Dallas-Fort Worth Texas Market, USA | Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across... ► Artikel lesen | |
CHRISTINA LAKE CANNABIS | 0,021 | 0,00 % | Cenovus shuts in Christina Lake oil sands production due to wildfires | ||
BETTER PLANT SCIENCES | 0,010 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
PSYCHED WELLNESS | 0,009 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Provides Comprehensive Investor Update | Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 95,92 | 0,00 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ... | Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up... ► Artikel lesen | |
DAIICHI SANKYO | 21,950 | -3,56 % | AstraZeneca And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial | LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated... ► Artikel lesen |